All conditions, products and recommendations have been revised to reflect current local drug scheduling and clinical practice...
Sydney, NSW (PRWEB) November 28, 2011
Elsevier Australia has released a second edition of 'Community Pharmacy: Symptoms, Diagnosis and Treatment' – an indispensible guide to identifying and treating patients within the community setting.
Fully revised and updated, 'Community Pharmacy: Symptoms, Diagnosis and Treatment, 2nd Edition' is the ultimate text for differential diagnosis of the symptoms most commonly seen by community pharmacists throughout Australia and New Zealand.
The first ANZ edition of Community Pharmacy, published in 2007, has come to be an essential aid for pharmacy undergraduate students as well as newly-qualified pharmacists. Established pharmacists will also benefit from the wealth of new information featured in this fully updated edition.
New content includes more than 12 new treatment medicines, eight new case studies, and the incorporation of current issues like weight loss products and pre-quit nicotine use, alternative treatments and complementary therapies.
All conditions, products and recommendations have been revised to reflect current local drug scheduling and clinical practice, and the book’s evidence base has been updated in line with sources including the National Prescribing Service, Australian Prescriber, Australian Medicines Handbook, the Therapeutic Guidelines and Pharmaceutical Society of Australia guidelines.
'Community Pharmacy: Symptoms, Diagnosis and Treatment 2nd Edition' features a wide range of pictures to help compare various disease states, along with symptom-specific pharmaceutical questions and algorithms for the purposes of differential diagnosis.
Organised by body system, the book includes evidence-based practice for over-the-counter (OTC) recommendations, along with discussion of the prevalence and epidemiology of, each condition.
This full-colour pharmacy text also offers students and instructors additional web-based resources through Elsevier’s Evolve online platform including additional images for dermatology and ophthalmology, additional case studies and an additional chapter on Evidence-Based Practice.
This new edition also has the added benefit of providing online activities for practicing pharmacists undertaking essential Continuing Professional Development. These activities have been accredited for 10 hours of Group 2 CPD (or 20 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan and have been accredited by the Australian Pharmacy Council.
Additional learning tools like practical prescribing summary tables, self-assessment questions, abbreviations and tips boxes covering product use advice ensure this edition of 'Community Pharmacy' remains an essential pharmacy resource.
For further information about 'Community Pharmacy: Symptoms, Diagnosis and Treatment, 2nd Edition', please visit: http://tiny.cc/83hqk
ABOUT THE AUTHORS
Dr Paul Rutter, BPharm, MRPharmS, PhD Dr Rutter is Principal Lecturer of the School of Pharmacy at the University of Wolverhampton, UK.
Dr David Newby, BPharm, PhD Dr Newby is an Associate Professor within the Faculty of Health at the University of Newcastle in NSW, Australia.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).